Prothena Co. PLC (NASDAQ:PRTA) – Research analysts at Oppenheimer issued their Q1 2018 earnings per share (EPS) estimates for shares of Prothena in a note issued to investors on Thursday, Zacks Investment Research reports. Oppenheimer analyst J. Olson anticipates that the biotechnology company will earn ($1.49) per share for the quarter. Oppenheimer has a “Buy” rating and a $70.00 price objective on the stock. Oppenheimer also issued estimates for Prothena’s Q2 2018 earnings at ($1.56) EPS, Q3 2018 earnings at ($1.67) EPS, Q4 2018 earnings at ($1.79) EPS, FY2018 earnings at ($6.51) EPS, FY2019 earnings at ($5.84) EPS, FY2020 earnings at ($2.11) EPS and FY2021 earnings at ($0.33) EPS.
Several other analysts have also recently commented on PRTA. Wedbush cut Prothena from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $75.00 to $55.00 in a report on Monday, November 20th. ValuEngine cut Prothena from a “hold” rating to a “sell” rating in a report on Friday, December 15th. Cantor Fitzgerald reissued a “buy” rating and issued a $65.00 price target on shares of Prothena in a report on Wednesday, December 20th. Zacks Investment Research cut Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, BidaskClub raised Prothena from a “strong sell” rating to a “sell” rating in a report on Thursday, January 11th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $74.55.
Shares of Prothena (NASDAQ:PRTA) traded up $0.07 during mid-day trading on Monday, hitting $34.66. The company’s stock had a trading volume of 179,897 shares, compared to its average volume of 483,885. The stock has a market cap of $1,346.41, a P/E ratio of -8.54 and a beta of 2.79. Prothena has a one year low of $27.19 and a one year high of $70.00.
Prothena (NASDAQ:PRTA) last announced its earnings results on Wednesday, February 14th. The biotechnology company reported ($1.24) earnings per share for the quarter, beating the consensus estimate of ($1.48) by $0.24. Prothena had a negative return on equity of 33.37% and a negative net margin of 556.84%. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.27 million. During the same period last year, the business posted ($1.41) EPS. The company’s revenue was up 33.9% on a year-over-year basis.
A number of hedge funds have recently modified their holdings of the stock. Woodford Investment Management Ltd raised its holdings in Prothena by 1.6% during the fourth quarter. Woodford Investment Management Ltd now owns 11,528,614 shares of the biotechnology company’s stock worth $325,223,000 after purchasing an additional 179,000 shares during the last quarter. State Street Corp raised its holdings in Prothena by 10.6% during the second quarter. State Street Corp now owns 1,181,365 shares of the biotechnology company’s stock worth $63,932,000 after purchasing an additional 113,193 shares during the last quarter. Alliancebernstein L.P. raised its holdings in Prothena by 11.2% during the fourth quarter. Alliancebernstein L.P. now owns 1,005,998 shares of the biotechnology company’s stock worth $37,715,000 after purchasing an additional 101,273 shares during the last quarter. Vanguard Group Inc. raised its holdings in Prothena by 1.9% during the second quarter. Vanguard Group Inc. now owns 713,084 shares of the biotechnology company’s stock worth $38,592,000 after purchasing an additional 13,226 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in Prothena by 1.3% during the fourth quarter. Jennison Associates LLC now owns 416,031 shares of the biotechnology company’s stock worth $15,597,000 after purchasing an additional 5,313 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: This story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://ledgergazette.com/2018/03/15/oppenheimer-weighs-in-on-prothena-co-plcs-q1-2018-earnings-prta.html.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.